SCHEMBL4674433

SCHEMBL4674433

COc1ccc(Cc2ccoc2C(=O)C=C(O)C(=O)O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.42
MAOB P27338 1/20 0.41
SAE1 Q9UBE0 1/20 0.39
UBA2 Q9UBT2 1/20 0.39
LDHA P00338 1/20 0.38
CTBP2 P56545 1/20 0.38
PDE3B Q13370 1/20 0.37
PDE3A Q14432 1/20 0.37
PDE10A Q9Y233 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ATM Q13315 1/20 0.37
ALDH1A1 P00352 1/20 0.37
USP2 O75604 1/20 0.36
TP53 P04637 1/20 0.36
GPR52 Q9Y2T5 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674429 1.00 LTA4H (0.42) LTA4HMAOBSAE1UBA2LDHA
SCHEMBL4674473 0.86 SRD5A2 (0.37) CTBP2MEN1KMT2AATMTP53
SCHEMBL4674471 0.86 SRD5A2 (0.37) CTBP2MEN1KMT2AATMTP53
SCHEMBL4674464 0.85 KMT2A (0.40) MAOBKMT2AALDH1A1GPR52NPC1
SCHEMBL4674462 0.85 KMT2A (0.40) MAOBKMT2AALDH1A1GPR52NPC1
SCHEMBL4672737 0.84 LMNA (0.48) MAOBKMT2AALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL4672735 0.84 LMNA (0.48) MAOBKMT2AALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL4670571 0.83 ITGB1 (0.35) MAOBMEN1KMT2AALDH1A1RAB9A
SCHEMBL4675595 0.83 ALDH1A1 (0.36) CTBP2MEN1KMT2AALDH1A1RAB9A
SCHEMBL4675592 0.83 ALDH1A1 (0.36) CTBP2MEN1KMT2AALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 LTA4H 2809/4885MAOB 158/4885SAE1 2206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.